CLINICAL TRIALS PROFILE FOR RUBRACA
✉ Email this page to a colleague
All Clinical Trials for RUBRACA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02740712 ↗ | Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | Completed | Clovis Oncology, Inc. | Phase 1 | 2016-04-01 | The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation. |
| NCT02855944 ↗ | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Active, not recruiting | Foundation Medicine | Phase 3 | 2017-03-01 | The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy. |
| NCT02855944 ↗ | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Active, not recruiting | Clovis Oncology, Inc. | Phase 3 | 2017-03-01 | The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy. |
| NCT02873962 ↗ | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | Recruiting | Bristol-Myers Squibb | Phase 2 | 2016-11-10 | This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer. |
| NCT02873962 ↗ | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | Recruiting | Dana-Farber Cancer Institute | Phase 2 | 2016-11-10 | This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer. |
| NCT02925234 ↗ | The Drug Rediscovery Protocol (DRUP Trial) | Recruiting | Amgen | Phase 2 | 2016-08-01 | This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RUBRACA
Condition Name
Clinical Trial Locations for RUBRACA
Trials by Country
Clinical Trial Progress for RUBRACA
Clinical Trial Phase
Clinical Trial Sponsors for RUBRACA
Sponsor Name
